Abiopharma

🔍 McBee Brannin (Executive)

Company: CoreWeave, Inc. (CRWV)

Report Date: 2026-03-23

Detailed Transactions and Holdings:

• Acquired 100,000 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 348,664.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 13,478 shares of Class A Common Stock at $81.0558 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 335,186.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 46,498 shares of Class A Common Stock at $81.8777 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 288,688.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Sold 11,800 shares of Class A Common Stock at $82.9811 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 276,888.00 | transaction_form_type: 4 | Footnotes: F2, F5
• Sold 18,978 shares of Class A Common Stock at $83.8089 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 257,910.00 | transaction_form_type: 4 | Footnotes: F2, F6
• Sold 9,246 shares of Class A Common Stock at $84.7347 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 248,664.00 | transaction_form_type: 4 | Footnotes: F2, F7
• Acquired 16,665 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 16,665.00 | transaction_form_type: 4 | Footnotes: F1, F8
• Sold 2,246 shares of Class A Common Stock at $81.0558 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 14,419.00 | transaction_form_type: 4 | Footnotes: F2, F9, F8
• Sold 7,749 shares of Class A Common Stock at $81.8777 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,670.00 | transaction_form_type: 4 | Footnotes: F2, F4, F8
• Sold 1,967 shares of Class A Common Stock at $82.981 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 4,703.00 | transaction_form_type: 4 | Footnotes: F2, F5, F8
• Sold 3,162 shares of Class A Common Stock at $83.8089 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,541.00 | transaction_form_type: 4 | Footnotes: F2, F6, F8
• Sold 1,541 shares of Class A Common Stock at $84.7346 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F7, F8
• Acquired 27,085 shares of Class A Common Stock (Direct)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 27,085.00 | transaction_form_type: 4 | Footnotes: F1, F10
• Sold 3,651 shares of Class A Common Stock at $81.0559 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 23,434.00 | transaction_form_type: 4 | Footnotes: F2, F9, F10
• Sold 12,593 shares of Class A Common Stock at $81.8777 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 10,841.00 | transaction_form_type: 4 | Footnotes: F2, F4, F10
• Sold 3,197 shares of Class A Common Stock at $82.981 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,644.00 | transaction_form_type: 4 | Footnotes: F2, F5, F10
• Sold 5,140 shares of Class A Common Stock at $83.8089 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,504.00 | transaction_form_type: 4 | Footnotes: F2, F6, F10
• Sold 2,504 shares of Class A Common Stock at $84.7348 per share (Direct)
  Date: 2026-03-23 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F7, F10
• Sold 100,000 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 7,691,660.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1
• Sold 16,665 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 2,196,975.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F8
• Sold 27,085 shares of Class B Common Stock (Derivative)
  Date: 2026-03-23 | Code: C | equity_swap_involved: 0 | shares_owned_after: 3,830,595.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1, F10

Footnotes:

• F1: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
• F2: The reported transaction represents a sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 17, 2025.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.37 to $81.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this filing.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.37 to $82.36, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.37 to $83.36, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.36, inclusive.
• F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.37 to $85.26, inclusive.
• F8: The reported securities are directly held by the reporting person's spouse.
• F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.37 to $81.36, inclusive.
• F10: The reported securities are directly held by the Brannin J. McBee 2022 Irrevocable Trust, of which the reporting person's spouse and minor child are beneficiaries and for which the reporting person's spouse serves as trustee.
• REMARKS: This Form 4 is Part 1 of 2 for this reporting person. Transactions by the reporting person are continued on Part 2.